Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2026-05-07 AGM Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Chair's Address to Shareholders 5 pages 273.8KB
AGM Information Classification · 95% confidence The document is a detailed text of the Chairman's Address at the 2026 Annual General Meeting (AGM) of Cyclopharm Limited. It includes a business update, financial performance highlights, strategic progress, board changes, and outlook for the company. The text explicitly mentions it is the Chairman's Address at the AGM and includes agenda items typical of an AGM presentation. The document is about 11,763 characters long, which is substantial and contains substantive content rather than just an announcement or a brief summary. It is not a full annual report (10-K) or an earnings release (ER), but rather materials shared during the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2026-05-07 English
Managing Director's Address to Shareholders 12 pages 275.3KB
AGM Information Classification · 95% confidence The document is a detailed presentation given at the 2026 Annual General Meeting (AGM) of Cyclopharm Limited. It includes the Managing Director's address, financial results for the full year 2025, trading highlights, business segment explanations, technology overview, and strategic outlook. The content is structured as slides and narrative typical of an AGM presentation. It discusses record revenues, market expansion, and strategic initiatives, which are common topics in AGM materials. There is no indication that this is the full Annual Report (10-K) or an earnings release (ER), nor is it a regulatory filing or certification. The presence of slides and the format strongly suggest this is presentation material shared at the AGM. Therefore, the document fits best under AGM Information (AGM-R).
2026-05-07 English
CYC 2026 AGM Presentation 38 pages 4.4MB
AGM Information Classification · 95% confidence The document is titled '2026 Annual General Meeting' and contains a detailed presentation including Chairman's and Managing Director's addresses, financial highlights for the full year 2025, business strategy, product information, market expansion, and clinical trial updates. The content is typical of materials shared during an Annual General Meeting (AGM) to inform shareholders and investors about company performance, strategy, and outlook. There is no indication that this is a full Annual Report (10-K) or an earnings release (ER), nor is it a regulatory filing or certification. The length (15,000 characters) and detailed presentation style further support it being AGM presentation materials. Therefore, the document fits the category of AGM Information (AGM-R).
2026-05-07 English
Results of Meeting 2 pages 219.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement dated 8 May 2026 from Cyclopharm Ltd regarding the results of their Annual General Meeting (AGM). It references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. The content includes detailed proxy vote counts and outcomes for resolutions passed at the AGM. The document is relatively short (3282 characters) and focuses solely on the voting results and proxies, not on the full AGM materials or presentations. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting. Therefore, the correct classification is DVA with high confidence.
2026-05-07 English
Final Director's Interest Notice - DH 2 pages 187.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held and interests in contracts, and notes the director ceased to be a director on a specific date. The content is focused on reporting personal share transactions and holdings of a company director. The document length is short (2245 characters) and contains no financial statements or company performance data. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2026-05-07 English
Final Director's Interest Notice - KB 2 pages 188.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's relevant interests in securities, including holdings by related parties. The content is focused on reporting personal share transactions or holdings by a company director. The document length is short (2247 characters) and it is a formal notice of director's share interests, which aligns with the definition of Director's Dealing filings. There is no financial performance data, no meeting materials, no voting results, no legal proceedings, or other report types. Therefore, the correct classification is Director's Dealing (DIRS).
2026-05-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.